Kornimate/medical-research-clean huggingface dataset:
famotidine outpatient covid-19 treatment study

Conditions: COVID-19

Summary: a retrospective case series of patients who self-medicated with famotidine during coronavirus disease 2019 (covid-19). the study will collect de-identified patient reported outcome measures of patients with confirmed covid-19 who self-medicated with famotidine at any dose during the period of illness. data will be collected by questionnaire and telephone interview. inclusion criteria: age\>18; ability to give written informed consent for study participation; confirmed diagnosis of covid-19; use of famotidine at any dose during period of covid-19 illness

famotidine is a histamine-2 receptor antagonist, widely available over-the-counter, and is safely used for suppression of gastric acid production over a wide range of doses from 20mg once daily to 160mg four times daily. in computer-based simulations, famotidine has been identified as a potential inhibitor of the 3-chymotrypsin-like protease (3clpro). in a propensity score matched retrospective cohort study a significantly reduced risk for death or intubation (adjusted hazard ratio 0.43, 95% confidence interval 0.21-0.88) was identified for patients with covid-19 who were taking famotidine before or at the point of hospital admission. some individuals have self-medicated with famotidine while being outpatients with covid-19. this study is aimed at collecting patient reported outcome measures from such individuals.

Eligibility criteria:
inclusion criteria: age \>18 years; ability to give written informed consent; confirmed covid-19 diagnosis; famotidine use during covid-19 illness exclusion criteria: none

Keywords: famotidine
carboxypeptidase-g2 in treating nervous system toxic effects in patients given an overdose of intrathecal methotrexate

Conditions: Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific

Summary: rationale: chemoprotective drugs such as carboxypeptidase-g2 may protect normal cells from the toxic effects of chemotherapy. purpose: clinical trial to study the effectiveness of carboxypeptidase-g2 in treating nervous system toxic effects in patients given an accidental overdose of intrathecal methotrexate.

objectives: * determine the effectiveness of carboxypeptidase-g2 rescue in patients who develop life threatening methotrexate (mtx) neurotoxicity following accidental intrathecal mtx overdose. * study the csf pharmacokinetics of mtx following rescue. outline: patients undergo a lumbar puncture as soon as possible after methotrexate overdose to remove methotrexate and receive a single dose of carboxypeptidase-g2 intrathecally over 5 minutes. patients are followed for at least 1 month. projected accrual: a maximum of 10 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * patients who received an intrathecal overdose of methotrexate of 100 mg or more patient characteristics: age: * any age performance status: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * no prior anaphylactic reaction to carboxypeptidase-g2 administration prior concurrent therapy: biologic therapy * not specified chemotherapy * see disease characteristics endocrine therapy * not specified radiotherapy * not specified surgery * not specified other * concurrent therapy allowed

Keywords: unspecified childhood solid tumor, protocol specific unspecified adult solid tumor, protocol specific neurotoxicity
bioequivalence study of verapamil

Conditions: Healthy Volunteers

Summary: the purpose of this study is to demonstrate bioequivalence of single doses of two verapamil formulations


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects * mass index (bmi) of approximately 18 to 30 kg/m2 exclusion criteria: * any condition possibly affecting drug absorption * a positive urine drug screen

Keywords: cardiovascular diseases hypertension
mechanisms of ischemic stroke in cancer patients

Conditions: Stroke; Cancer

Summary: the purpose of this study is to better understand the causes of stroke in people with cancer. active cancer increases the risk of stroke. the investigators do not know exactly why this occurs but one possible reason is that people with cancer may have thicker blood than people without cancer. thick blood can sometimes cause blood clots to form in the heart, which can then travel to the brain and cause stroke. this study is being done to help figure out why this and other causes of stroke occur in people with cancer. the investigators expect that information from this study will help doctors to more effectively prevent and treat stroke in individuals with cancer.

this will be a prospective cross-sectional study to examine the unique mechanisms of ischemic stroke in cancer patients. enrollment will occur at the newyork-presbyterian hospital (nyph)/weill cornell medical center (wcmc) and the memorial sloan kettering cancer center (mskcc). measurements will occur at the nyph/wcmc and mskcc neurovascular ultrasound laboratories, the mskcc central laboratory, and the sharp laboratory at the university of california, davis. three groups of adult patients will be enrolled. group 1 will consist of consecutive patients with active solid tumor cancer and acute ischemic stroke. group 2 will be patients with acute ischemic stroke and no cancer. patients in groups 1 and 2 will be enrolled at 96 hours +/- 24 hours of stroke onset. group 3 will include patients with active solid tumor cancer and no stroke. this group will allow us to confirm that differences between stroke patients with and without cancer are not simply incidental findings that can be expected in all cancer patients regardless of thrombotic status. demographics, comorbidities, and stroke severity (for groups 1 and 2 only) will be recorded on admission using a structured form. study patients will undergo three facets of testing: 1) transcranial doppler (tcd) microemboli detection; 2) hematological biomarker testing; 3) peripheral blood leukocyte rna gene expression analysis.

Eligibility criteria:
inclusion criteria * 18 years of age or older * active solid tumor cancer (for groups 1 and 3 only) * mri confirmed acute ischemic stroke (for groups 1 and 2 only) * available for blood draw at 96 hours (+/- 24 hours) from last known well time (for groups 1 and 2 only) or within 2 weeks of enrollment (for group 3) * available for tcd within 2 weeks of enrollment exclusion criteria * primary brain tumor or hematological cancer * treatment with intravenous or intraarterial thrombolysis or mechanical embolectomy * platelets \< 50,000/mm3 * hemodialysis within 14 days * active pregnancy * infection within 14 days per infectious diseases society of america (idsa) criteria

Keywords: biomarkers mechanisms transcranial doppler
randomized, controlled study of cf patients between 3 months and less than 7 years

Conditions: Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients

Summary: this study investigated the efficacy of inhaled tobi treatment for early infections of p. aeruginosa in paediatric patients with cystic fibrosis.


Eligibility criteria:
inclusion criteria: * diagnosis of cystic fibrosis * early lower respiratory tract infection with p. aeruginosa, exclusion criteria: * known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics. * administration of loop diuretics within 7 days prior to study drug administration. * other protocol-defined inclusion/exclusion criteria may apply

Keywords: tobramycin inhalation solution cystic fibrosis lung disease anti-bacterial agents
a placebo-controlled trial of clbs16 in subjects with coronary microvascular dysfunction

Conditions: Coronary Microvascular Dysfunction; Coronary Microvascular Disease; Microvascular Coronary Artery Disease

Summary: this clinical trial will explore the efficacy and safety of gcsf-mobilized autologous cd34+ cells for the treatment of cmd in adults currently experiencing angina and with no obstructive coronary artery disease. eligible subjects will receive a single administration of clbs16 or placebo.


Eligibility criteria:
inclusion criteria: * men or women age ≥18 * history of and currently experiencing angina at least 3 times per week * prior diagnosis of cmd based on coronary flow reserve (cfr) ≤ 2.5 or other measures * canadian cardiovascular society (ccs) class ii, iii or iv chronic refractory angina * no obstructive coronary artery disease * on stable medical therapy for at least 30 days prior to enrollment * must agree to use a reliable and acceptable method of contraception for the duration of participation * written informed consent exclusion criteria: * myocardial infarction within 90 days * prior evidence of obstructive heart disease including pci or cabg (or planned pci or cabg) * diagnosis of other specific cardiac disease * must meet lvef and gfr requirements * current use of coumadin or doacs * hypersensitivity to gcsf, apheresis or study product components * positive for hiv, hepatitis b or hepatitis c * active inflammatory or autoimmune disease, or chronic immunosuppressive state * drug abuse * pregnant or lactating * malignant neoplasm within 5 years * history of sickle cell disease * participation in another clinical study within 90 days prior to informed consent or concurrently with this study * previous treatment with a cd34+ cell based therapy

Keywords: angina cmd mvd non-obstructive coronary artery disease
safety and tolerability of sacubitril/valsartan in heart failure patient with reduced ejection fraction

Conditions: Heart Failure, Systolic

Summary: this proof-of-concept, open-label non-randomized clinical trial was conducted at a tertiary care cardiac center in karachi, pakistan. patients with hfref were prescribed sacubitril/valsartan and followed for 12 weeks for the assessment of safety and tolerability. safety measures included incidence of hypotension, renal dysfunction, hyperkalemia, and angioedema

a required number of consecutive patients meeting the inclusion criteria were recruited for this study. after written informed consent patient demographic and baseline clinical characteristics were obtained. inclusion criteria for the study were either gender between 18 to 80 years of age, diagnosed with congestive heart failure (chf) with nyha class ii-iv, and lvef ≤ 40%. pre-inclusion safety parameters were patients who were stable on any dose of beta-blockers, angiotensin-converting enzyme inhibitor (acei) or angiotensin receptor blocker (arb) prior to enrolment in the study. patients with a baseline diagnosis of hyperkalemia, hypotension, renal dysfunction, and a history of hypersensitivity to the active substances, sacubitril/valsartan, or to any of the excipients or drugs of similar chemical classes were excluded from the study. all the recruited patients were prescribed sacubitril/valsartan 100mg/200mg twice a day (bid) for 6 weeks. a weekly telephonic follow-up was made to assess the patient's medication adherence level using the dose-nonadherence scale. all the patients were kept under a close follow-up for 6 weeks period and at the end of 12 weeks of medication, the safety and tolerability outcomes were assessed as per the operational definition.

Eligibility criteria:
inclusion criteria: * either gender * between 18 to 80 years of age * diagnosed with heart failure with reduced ejection fraction (hfref) * new york heart association (nyha) class ii-iv * left ventricular ejection fraction (lvef) ≤ 40% * stable on any dose of beta-blockers, acei or arb exclusion criteria: * refused to participate in the study * patients with hyperkalemia * patients with hypotension * patients with renal dysfunction * history of hypersensitivity to the active substances, sacubitril/valsartan, or to any of the excipients or drugs of similar chemical classes
the effect of stress ball use on comfort, anxiety, and patient satisfaction in hemodialysis patients

Conditions: Hemodialysis Patients

Summary: chronic kidney disease represents a significant public health issue both in türkiye and worldwide, with the majority of patients undergoing hemodialysis treatment. individuals receiving hemodialysis often experience not only physical discomfort but also psychological distress, including heightened anxiety and reduced comfort. the aim of this study is to evaluate the effects of stress ball use on comfort, anxiety, and patient satisfaction among hemodialysis patients. the stress ball is a simple and cost-effective non-pharmacological intervention that aids individuals in managing stress by redirecting their attention. notably, this study is unique in simultaneously investigating comfort, anxiety, and satisfaction parameters within this patient population.


Eligibility criteria:
inclusion criteria: * being 18 years of age or older * being literate * having no visual or hearing impairments * being able to communicate verbally * having no physical disability that would prevent the use of a stress ball * not having a diagnosed anxiety disorder and not using medication for it * willingness to participate in the study exclusion criteria: * currently using sedative medications * having a diagnosed psychiatric disorder * having any physical limitation that prevents squeezing a stress ball
subcuticular suture versus staples for closure of the skin after caesarean section.

Conditions: Cesarean Section; Cicatrix

Summary: the purpose of this study is to compare two methods for closure of the skin after caesarean section on the same patient; staples and subcuticular sutures. the study is performed on two separate groups of patients: 1. woman having cesarean section for the first time and have not previously had abdominal surgery through a lower abdominal transverse incision. 2. woman, who have previously had a caesarean section done. the following parameters are registered: 1. an objective evaluation of the two ends of the scar 6 months postoperatively. 2. a patient evaluation of the two ends of the scar 6 months postoperatively. 3. the difference in pain in the two ends of the scar 1 day postoperatively (blinded). 4. the difference in pain in the two ends of the scar 7 days, 3 and 6 months postoperatively. 5. the rate of infection.


Eligibility criteria:
inclusion criteria: * woman having elective or level iii caesarean section. level iii caesarean section is defined as being ordered more than 30 minutes before surgery is started. * woman who speak and understand danish * woman who can give informed consent. exclusion criteria: * level i or ii caesarean section (ordered less than 30 min. before surgery is started). * diabetics (this does not include gestational diabetes). * infection * regular treatment with immunosuppressives * alcohol or drug abuse * age under 18 * chronic pain disease eg fibromyalgia, rheumatoid arthritis * bmi over 35 * previous abdominal surgery through lower transverse abdominal incision (only applicable to woman having caesarean section for the first time).

Keywords: cicatrix cesarean section sutures surgical staples postoperative pain infection
evaluation of tamsulosin in the treatment of ureteral stones

Conditions: Ureterolithiasis; Ureteral Calculi

Summary: ureteral stones have an important place in daily urological practice, usually causing acute episodes of ureteral colic by obstructing the urinary tract. the aim of the study is to evaluate whether repeated administration of tamsulosin, a drug routinely used in the treatment of lower urinary tract symptoms, could lower the delay of elimination of the stone in patients with pelvis ureterolithiasis.

ureteral colic, mainly due to ureterolithiasis, represents 1 to 2% of hospital emergency admissions. when a surgical intervention is not required, usual treatment combines hydration and anti-inflammatory drugs. alpha1-blockers, firstly developed as anti-hypertensive drugs, are now also used in the management of benign prostatic hyperplasia, due to their relaxing properties on the urinary tract. the aim of the study is to investigate whether tamsulosin could lower the delay of elimination of the stone in patients with pelvis ureterolithiasis. patients are randomized to receive either tamsulosin or a placebo in addition to usual treatment until stone elimination. efficacy is assessed by evaluating the time to spontaneous passage of the stone between day 1 and day 42, the need for surgery and pain recurrences.

Eligibility criteria:
inclusion criteria: * adult over 18 years * emergency admission for a ureteral colic * radio-opaque ureterolithiasis * stone of 2 to 7 mm diameter * informed written consent exclusion criteria: * pregnancy or breast-feeding * treatment with alpha or beta-blocker * contraindication to tamsulosin (orthostatic hypertension, hepatic failure) * complication needing surgery * calculi spontaneous passage before randomization * patient not available for a 6 week follow-up

Keywords: ureterolithiasis alpha1-blocker lower ureteral stone
chromosomal analysis of single cells in human embryos

Conditions: Chromosomal Abnormalities

Summary: optimise genetic screening of human embryos using higher resolution techniques


Eligibility criteria:
inclusion criteria: * 3-4 day old embryos from ivf couples with both partners younger than 36 years old

Keywords: chromosomal abnormalities in single cells
urinary t cell biomarker for prediction in anca glomerulonephritis

Conditions: Glomerulonephritis Acute

Summary: urinary t lymphocytes may be predictive for clinical outcome in patients with anca associated glomerulonephritis (anca gn). the investigators hypothesize that the amount of cd4+ effector/memory t cells in urine at time of diagnosis predicts the outcome of patients with active anca gn after 6 months of therapy. in a prospective, six-months follow-up study patients' urine will be analysed by flow cytometry every 60 days (+/- 10d). treatment will be performed to the discretion of the treating clinician. after 6 months of treatment response will be determined as either complete response or partial response.


Eligibility criteria:
inclusion criteria: * informed consent * biopsy proven anca related glomerulonephritis * in absence of biopsy clinical diagnosis of anca related glomerulonephritis exclusion criteria: * biopsy proven non-anca related kidney disease * active menstrual bleeding * urinary tract infection * kidney transplantation during observational period

Keywords: anti-neutrophil cytoplasmic antibody-associated vasculitis pauci-immune vasculitis churg-strauss syndrome granulomatosis with polyangiitis microscopic polyangiitis urinary biomarker outcome prediction, urinary effector memory t lymphocytes glomerulonephritis non-invasive biomarker flow cytometry treatment outcome cd4-positive t-lymphocytes/immunology
pneumatic compression treatment for upper extremity acquired lymphedema

Conditions: Lymphedema

Summary: the purpose of this study is to determine how well different treatments for acquired lymphedema work. the study will compare 5 different non-invasive treatments for acquired lymphedema of the arm to see which treats lymphedema best.

this study will compare 5 non-invasive lymphedema treatments. patients will be assigned to either: - a combination of arm exercises, arm elevation, and wearing of a compression garment every day or - one of four possible pneumatic compression devices for just two hours every day. pneumatic compression devices are made up of an inflatable sleeve connected to a small controller unit that is plugged into the wall. they feel like having your blood pressure taken. none of the treatments are experimental. none of the treatments are invasive. all the treatments are considered standard of care and are used in clinics throughout the united states. all of the treatments will be done at home. the trial will last for 7 and 1/2 months and will require follow-up visits to monitor progress.

Eligibility criteria:
inclusion criteria: * patients diagnosed with acquired lymphedema of the arm. exclusion criteria: * refusal of consent * unlikely compliance with the research protocol * acute upper extremity dvt

Keywords: lymphedema breast cancer upper extremity arm
chest pnf on pulmonary function in parkinson disease

Conditions: Parkinson Disease

Summary: background: parkinson disease (pd) is a progressive neurodegenerative disorder and characterized by tremor, rigidity and bradykinesia. almost 84% of pd patient develops respiratory abnormalities and pointed as the most common cause of death. airway obstruction, trunk muscle rigidity is the common cause of respiratory abnormalities. purpose: the main purpose of the study will evaluate the efficacy of chest pnf on pulmonary function and chest wall mobility in pd. methods: 20 participants will be recruited for study purpose and divide into two groups. group= a will be the control group and participants will receive conventional treatment which includes deep breathing exercise and segmental breathing exercise, incentive spirometry etc for one week. group= b participants will receive chest pnf exercise along with conventional treatment for a week. pretreatment and post-treatment data will be recorded by the help of pft (fvc, fev1 \& fev1/fvc) and chest wall expansion at axillary and xiphisternal level for data analysis. data analysis will be done by paired t-test for within group and independent t-test will be used for the between-group variable. the level of significance will be set at 0.05.


Eligibility criteria:
inclusion criteria: 1. grade 3 to grade 5 parkinson patients according to hoehn yahar scale 2. mmse score \>23. 3. age 50-70 yrs. 4. both male and female. exclusion criteria: 1. previous history of cardiac and pulmonary surgery. 2. history of flail chest. 3. individual affected by neurological disorder other than pd. 4. uncooperative patients. 5. individual with the psychosomatic disorder.
senior-covid-rea multicentric survey

Conditions: COVID-19 Disease, Severe Form

Summary: with the spread of covid-19 epidemic since 2019 in wuhan, china health plans have to be adapted continuously in response to the emergency. the first publications from the chinese experience demonstrate an increase in the incidence of covid-19 infections in patients over 60 years of age, a higher frequency of severe forms of the disease and therefore theoretical indications of orientation towards resuscitative care. however, the first published data from hubei province suggest a low benefit of resuscitation for patients between 70 and 80 years of age and null in patients over 80 years of age. these data question the individual benefit / risk balance of an orientation towards resuscitation for this category of patients, their quality of life and the concept of unreasonable obstinacy. among the covariates associated with resuscitation mortality described in the data published to date, cardiovascular comorbidities, certain biological covariates (ldh, creatinine, lymphocytes, neutrophils, tp, d-dimers, etc.), the time between the first symptoms and the entry into resuscitation have been identified. the objective of this multicentric observational study is to determine the clinical and biological covariates predictive of mortality in the population of patients over 60 years of age admitted in intensive care unit, in particular by integrating functional and nutritional data from patients 1 month before covid-19 infection.


Eligibility criteria:
inclusion criteria: * patient over 60 * sent to the intensive care unit * whose covid diagnosis has been established (rt-pcr and / or chest scanner) exclusion criteria: * refusal of the patient or his support person to participate in the study